Letter to the Editor

References

1. 1.↵
   1. Martinez J. E.

   Hyperthermophilic microorganisms and USP hot water systems. Pharm. Technol. 2004, 28 (2), 50–65.

   OpenUrl
2. 2.↵
   1. Sutton S. V. W.

   Disinfectant rotation—a microbiologist's view. Controlled Environ. 2005, July, 9– 14.
3. 3.↵
   1. Martinez J.

   The rotation of disinfectants principle: true or false? Pharm. Technol. 2009, 33 (2), 58– 71.

   OpenUrl
4. 4.↵
   1. Kuhn R. J.,
   2. Lubin A. H.,
   3. Jones P. R.,
   4. Nahata M. C.

   Bacterial contamination of aerosol solutions used to treat cystic fibrosis. Am. J. Hosp. Pharm. 1982, 39 (2), 308–309.

   OpenUrlPubMed
5. 5.↵
   USP. Microbial contamination of sterile and non-sterile articles, with special reference to Pseudomonas cepacia. Pharm. Forum 1982, 8 (4), 2239.

   OpenUrl
6. 6.↵
   FDA. Guide to Inspections of Microbiological Pharmaceutical Quality Control Laboratories, 1993. http://www.fda.gov/ora/inspect_ref/igs/micro.html.
7. 7.↵
   1. Springman A.,
   2. Jacobs J. L.,
   3. Somvanshi V. S.,
   4. Sundin G. W.,
   5. Mulks M. H.,
   6. Whittam T. S.,
   7. Viswanathan P.,
   8. Gray R. L.,
   9. Lipuma J. J.,
   10. Ciche T. A.

   Genetic diversity and multihost pathogenicity of clinical and environmental strains of Burkholderia cenocepacia. Appl. Environ. Microbiol. 2009, 75 (16), 5250–5260.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Baldwin A.,
   2. Mahenthiralingam E.,
   3. Drevinek P.,
   4. Vandamme P.,
   5. Govan J. R.,
   6. Waine D. J.,
   7. LiPuma J. J.,
   8. Chiarini L.,
   9. Dalmastri C.,
   10. Henry D. A.,
   11. Speert D. P.,
   12. Honeybourne D.,
   13. Maiden M. C.,
   14. Dowson C. G.

   Environmental Burkholderia cepacia complex isolates in human infections. Emerg. Infect. Dis. 2007, 13 (3), 458–461.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Ramette A,
   2. LiPuma J. J.,
   3. Tiedje J. M.

   Species abundance and diversity of Burkholderia cepacia complex in the environment. Appl Environ Microbiol. 2005, 71 (3), 1193–1201.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    FDA. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice, 2004.
11. 11.↵
    1. Hussong D.,
    2. Madsen R. E.

    Analysis of environmental microbiology data from cleanroom samples. Pharm. Technol. 2004, Aseptic Processing Supplement, 10–15.
12. 12.↵
    1. Farrington J. K.

    Environmental monitoring in pharmaceutical manufacturing—a product risk issue. Am. Pharm. Rev. 2005, 8 (4), 26–30.

    OpenUrl
13. 13.↵
    1. Kutty P.,
    2. Moody B.,
    3. Gullion J. S.,
    4. Zervos M.,
    5. Ajluni M.,
    6. Washburn R.,
    7. Sanderson R.,
    8. Kainer M. A.,
    9. Powell T. A.,
    10. Clarke C. F.,
    11. Powell R. J.,
    12. Pascoe N.,
    13. Shams A.,
    14. LiPuma J. J.,
    15. Jensen B.,
    16. Noble-Wang J.,
    17. Arduino M. J.,
    18. McDonald L. C.

    Multistate outbreak of Burkholderia cenocepacia colonization and infection associated with the use of intrinsically contaminated alcohol-free mouthwash. Chest 2007, 132 (6), 1825–1831.

    OpenUrlCrossRefPubMed